By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

NCT ID: NCT03880721

Last Updated: 2019-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Good prognosis

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Poor prognosis

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Recurrence

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Not Recurrence

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Survival

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Death

Microwave abaltion

Intervention Type PROCEDURE

Use microwave ablation to treat hepatocellular carcinoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microwave abaltion

Use microwave ablation to treat hepatocellular carcinoma

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with primary hepatocellular carcinoma in the department of interventional ultrasound, PLA general hospital, who accept MWA therapy for HCC


1. Primary hepatocellular
2. No other treatments ware performed before microwave ablation
3. Patient has been clinically diagnosed with HCC definitely, and have a definite operational indication
4. No extrahepatic manifestations and no evidence of vessel invasion and bile duct thrombi

Exclusion Criteria

1. Non-primary hepatocellular carcinoma or hepatic metastases
2. Accept other treatment before microwave ablation
3. Extrahepatic metastasis, vessel invasion or bile duct thrombi
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese PLA General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ping Liang

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jie Yu, Dr

Role: CONTACT

8610-66939530

Ping Liang, Dr

Role: CONTACT

8610-66939530

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ping Liang, Doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

301jrcsk4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ga-68 Dolacga PET Scan in HCC Under RFA
NCT06792097 NOT_YET_RECRUITING